Disease Domain | Count |
---|---|
Infectious Diseases | 4 |
Immune System Diseases | 2 |
Neoplasms | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Unknown | 2 |
Synthetic peptide | 2 |
Vaccine | 1 |
Immunoglobulin | 1 |
Target |
Mechanism Chaperonin stimulators |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RANK inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date26 May 2023 |
Sponsor / Collaborator |
Start Date16 Mar 2023 |
Sponsor / Collaborator |
Start Date20 Dec 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
IRL-201805 ( RANK x RANKL ) | Uveitis, Posterior More | Phase 2 |
PIN-201104 ( Chaperonin ) | Eosinophilic Esophagitis More | Phase 2 |
ISR-50 | Tuberculosis More | Preclinical |
PIN-201601 ( Chaperonin ) | Bone Diseases More | Preclinical |
ISR-51 | Hepatitis B More | Preclinical |